Tubulis

Tubulis develops antibody-drug conjugates (ADCs) with indication-tailored targeting molecules and payloads. Their proprietary platform allows for customizable ADCs with superior properties, addressing key bottlenecks in ADC development. The company focuses on solid tumor indications.

Funding Round: Series B2

Funding Amount: €128M

Date: 14-Mar-2024

Investors: EQT Life Sciences, Nextech Invest Ltd, Frazier Life Sciences, Deep Track Capital, Andera Partners, BioMedPartners, Fund+, Bayern Kapital, Evotec, coparion, Seventure Partners, OCCIDENT, High-Tech Gründerfonds (HTGF)

Markets: Biotechnology, Oncology, Pharmaceuticals, Therapeutics, Life Science, Drug Discovery

HQ: Munich, Bavaria, Germany

Founded: 2012

Website: https://tubulis.com/

LinkedIn: https://www.linkedin.com/company/tubulis/

Twitter: https://twitter.com/tubulis_gmbh

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/tubulis-technologies

Pitchbook: https://pitchbook.com/profiles/company/183642-31